These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 21817082)

  • 1. Dabigatran etexilate: A novel oral direct thrombin inhibitor.
    Blommel ML; Blommel AL
    Am J Health Syst Pharm; 2011 Aug; 68(16):1506-19. PubMed ID: 21817082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases.
    Baetz BE; Spinler SA
    Pharmacotherapy; 2008 Nov; 28(11):1354-73. PubMed ID: 18956996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dabigatran etexilate: future directions in anticoagulant treatment.
    Schulman S; Reilly PA
    Clin Appl Thromb Hemost; 2009; 15 Suppl 1():32S-41S. PubMed ID: 19679590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dabigatran etexilate: a possible replacement for heparinoids and vitamin K antagonists?
    Guay DR
    Hosp Pract (1995); 2011 Feb; 39(1):105-25. PubMed ID: 21441766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dabigatran etexilate: a review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation.
    Garnock-Jones KP
    Am J Cardiovasc Drugs; 2011; 11(1):57-72. PubMed ID: 21265583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dabigatran etexilate in venous thromboembolism.
    Ferrer E
    Drugs Today (Barc); 2009 Oct; 45(10):715-24. PubMed ID: 20069135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dabigatran etexilate versus warfarin as the oral anticoagulant of choice? A review of clinical data.
    Ma TK; Yan BP; Lam YY
    Pharmacol Ther; 2011 Feb; 129(2):185-94. PubMed ID: 20920530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dabigatran etexilate: a novel oral thrombin inhibitor for thromboembolic disease.
    Bovio JA; Smith SM; Gums JG
    Ann Pharmacother; 2011 May; 45(5):603-14. PubMed ID: 21540406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor.
    Stangier J; Clemens A
    Clin Appl Thromb Hemost; 2009; 15 Suppl 1():9S-16S. PubMed ID: 19696042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dabigatran for stroke prevention in atrial fibrillation: the RE-LY trial.
    Paikin JS; Haroun MJ; Eikelboom JW
    Expert Rev Cardiovasc Ther; 2011 Mar; 9(3):279-86. PubMed ID: 21438804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dabigatran etexilate: a review of its use for the prevention of venous thromboembolism after total hip or knee replacement surgery.
    Burness CB; McKeage K
    Drugs; 2012 May; 72(7):963-86. PubMed ID: 22564134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice.
    Huisman MV; Lip GY; Diener HC; Brueckmann M; van Ryn J; Clemens A
    Thromb Haemost; 2012 May; 107(5):838-47. PubMed ID: 22318514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate.
    Stangier J
    Clin Pharmacokinet; 2008; 47(5):285-95. PubMed ID: 18399711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Warfarin versus dabigatran etexilate: an assessment of efficacy and safety in patients with atrial fibrillation.
    Dzeshka MS; Lip GY
    Expert Opin Drug Saf; 2015 Jan; 14(1):45-62. PubMed ID: 25341529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dabigatran etexilate for thromboembolic prophylaxis in non-valvular atrial fibrillation: the RE-LY study and substudies with commentary.
    Waks JW; Zimetbaum PJ
    Expert Rev Cardiovasc Ther; 2013 Nov; 11(11):1461-71. PubMed ID: 24147516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dabigatran etexilate: a new thrombin inhibitor.
    Verma AK
    Med J Aust; 2010 Apr; 192(7):407-12. PubMed ID: 20367591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dabigatran etexilate, a new oral direct thrombin inhibitor, for stroke prevention in patients with atrial fibrillation.
    Siddiqui FM; Qureshi AI
    Expert Opin Pharmacother; 2010 Jun; 11(8):1403-11. PubMed ID: 20446854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dabigatran etexilate in clinical practice: confronting challenges to improve safety and effectiveness.
    Gulseth MP; Wittkowsky AK; Fanikos J; Spinler SA; Dager WE; Nutescu EA
    Pharmacotherapy; 2011 Dec; 31(12):1232-49. PubMed ID: 22122184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatments for stroke prevention in atrial fibrillation: a network meta-analysis and indirect comparisons versus dabigatran etexilate.
    Roskell NS; Lip GY; Noack H; Clemens A; Plumb JM
    Thromb Haemost; 2010 Dec; 104(6):1106-15. PubMed ID: 20967400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pharmacology and therapeutic use of dabigatran etexilate.
    Sarah S
    J Clin Pharmacol; 2013 Jan; 53(1):1-13. PubMed ID: 23400738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.